HC Wainwright Cuts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $52.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target cut by HC Wainwright from $54.00 to $52.00 in a research note released on Tuesday, Marketbeat reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.60) EPS, FY2026 earnings at ($6.84) EPS, FY2027 earnings at ($5.35) EPS, FY2028 earnings at ($4.15) EPS, FY2029 earnings at ($2.29) EPS and FY2030 earnings at $0.64 EPS.

AGIO has been the subject of several other research reports. Bank of America lifted their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Truist Financial upped their price objective on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. JPMorgan Chase & Co. lowered their price objective on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. The Goldman Sachs Group raised their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $42.78.

Agios Pharmaceuticals Stock Up 0.6%

AGIO stock opened at $36.28 on Tuesday. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The company has a fifty day simple moving average of $33.73 and a two-hundred day simple moving average of $30.63. The firm has a market capitalization of $2.16 billion, a P/E ratio of -5.00 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, topping analysts’ consensus estimates of ($1.81) by $0.12. The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $13.30 million. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. Agios Pharmaceuticals’s revenue was up 137.7% compared to the same quarter last year. As a group, analysts anticipate that Agios Pharmaceuticals will post -6.33 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $25,000. Assetmark Inc. grew its position in Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 362 shares during the last quarter. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in Agios Pharmaceuticals in the fourth quarter worth $49,000. Finally, Quantbot Technologies LP purchased a new stake in Agios Pharmaceuticals in the third quarter worth $79,000.

Key Stories Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $52 price target on Agios, while lifting multiple long-term earnings estimates for 2027–2030. The firm also published a note saying AGIO appears positioned to beat upcoming earnings expectations, which can support investor sentiment ahead of the Q2 report.
• Neutral Sentiment: The updated analyst forecast for FY2026 was slightly worse, with HC Wainwright trimming its EPS estimate, but the broader message remained constructive because the firm still expects profitability to improve over time.
• Negative Sentiment: Recent news that Agios scrapped the tebapivat sickle cell disease program continues to weigh on the stock. The company ended development after phase II data showed target engagement but not enough clinical differentiation, raising concerns about pipeline execution.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.